Abstract: An antimicrobial peptide Scyampcin44-63, a formula of the antimicrobial peptide Scyampcin44-63 is C113H188N30O24S2, and an amino acid sequence of the antimicrobial peptide Scyampcin44-63 is SEQ ID NO: 01 with the C-terminus being amidated.

Abstract: Embodiments of this application disclose a data interface equalization adjustment method and apparatus, a device, and a storage medium, and relate to the field of data interface technologies. The method includes: A second device determines equalization parameter indication information of a first transmitter TX on a first data interface. The second device sends a first equalization training sequence block ETSB to a corresponding RX on the first data interface through a TX on a second data interface, where the first ETSB carries the equalization parameter indication information and equalization target indication information, and the equalization target indication information indicates that the first TX is an equalization target. The first device determines the equalization target to be the first TX based on the equalization target indication information, and adjusts an equalization parameter of the first TX to an equalization parameter indicated by the equalization parameter indication information.

Abstract: Provided are a method and a kit for constructing a simplified genomic library. The method comprises: performing a non-specific amplification on a whole genome with a first pair of primers to obtain random amplified fragments; performing a specific amplification on the random amplified fragments with a second pair of primers to obtain the simplified genomic library.

Abstract: A Spampcin56-86 is provided. A molecular formula of Spampcin56-86 is C154H256N54O33S3, and an amino acid sequence of Spampcin56-86 is shown in SEQ ID NO: 01.

Abstract: A data interface sleep and wakeup method includes receiving data information sent by a second electronic device, where the data information includes sleep information, and setting, based on the sleep information, at least one data interface to either a sleep state or a wakeup state.

Abstract: The present disclosure discloses an antimicrobial peptide Scyreprocin of Scylla paramamosain and a method thereof, wherein an amino acid sequence of the antimicrobial peptide Scyreprocin comprises a sequence shown in SEQ ID NO 01, and the antimicrobial peptide is expressed and purified by using genetic engineering technology. The recombinant antimicrobial peptide Scyreprocin has advantages of wide antimicrobial spectrum, good antimicrobial effect, and rapid germicidal rate, shows great application significance, and has good application in preparation of antimicrobial agents. The recombinant antimicrobial peptide Scyreprocin has no cytotoxicity to mouse hepatocytes AML12, human liver cells L02, and can be safely used for medical treatment or can be used as a feed composition.

Abstract: A peptide Scyreprocin of Scylla paramamosain, an amino acid sequence of the peptide Scyreprocin is SEQ ID NO 01.

Abstract: The present disclosure discloses an antimicrobial peptide AS-hepc3(48-56) of Acanthopagrus schlegelii and method thereof. A molecular formula of the antimicrobial peptide AS-hepc3(48-56) is C48H86N24O10S3, and an amino acid sequence of the antimicrobial peptide AS-hepc3(48-56) is SEQ ID NO: 01.

Abstract: Device for creating an emulsion consisting of a dispersed phase in the form of drops in a continuous phase, the device comprising: a motion generator (11) in order to put into motion at least one first fluid (3) intended to form the dispersed phase; a first channel (21) inside which the first fluid (3) put into motion can flow, the first channel (21) extending towards an output orifice (23) through which the first fluid is injected into at least one second fluid (5) intended to form the continuous phase; a variation system (40) for varying the internal volume (Vi) of the first channel (21) over time.

Abstract: Provided is an antimicrobial peptide Sparamosin from Scylla paramamosain. The Sparamosin mature peptide and its functional domain Sparamosin26-54 were synthesized by solid-phase synthesis with a purity of over 95%. Both Sparamosin and Sparamosin26-54 exhibit strong antimicrobial activity. More importantly, Sparamosin26-54 has strong antifungal activity and could inhibit the growth of a variety of yeasts and filamentous fungi. Based on the potent antimicrobial activities of Sparamosin and Sparamosin26-54, both peptides could be developed as alternatives for conventional antibiotics, antimicrobial agents, feed additives in aquaculture and livestock, preservatives, and mold inhibitors.

Abstract: The present disclosure discloses a method for using plant heterosis. The method comprises the following steps: S1, transforming the meiosis of germ cells of hybrids into mitosis-like so as to obtain gametes whose genotype and chromosome ploidy are consistent with hybrids by using gene mutation or gene engineering technology; and S2, influencing and involving in the development of gametes or embryos in plants by using gene mutation and gene engineering technology, wherein a protein involved is MTL protein.

Abstract: The present disclosure discloses an antimicrobial peptide AS-hepc3(48-56) of Acanthopagrus schlegelii and method thereof. A molecular formula of the antimicrobial peptide AS-hepc3(48-56) is C48H86N24O10S3, and an amino acid sequence of the antimicrobial peptide AS-hepc3(48-56) is SEQ ID NO: 01.

Abstract: The present disclosure discloses an antimicrobial peptide Scyreprocin of Scylla paramamosain and a method thereof, wherein an amino acid sequence of the antimicrobial peptide Scyreprocin comprises a sequence shown in SEQ ID NO 01, and the antimicrobial peptide is expressed and purified by using genetic engineering technology. The recombinant antimicrobial peptide Scyreprocin has advantages of wide antimicrobial spectrum, good antimicrobial effect, and rapid germicidal rate, shows great application significance, and has good application in preparation of antimicrobial agents. The recombinant antimicrobial peptide Scyreprocin has no cytotoxicity to mouse hepatocytes AML12, human liver cells L02, and can be safely used for medical treatment or can be used as a feed composition.

Abstract: Provided is an antimicrobial peptide Sparamosin from Scylla paramamosain. The Sparamosin mature peptide and its functional domain Sparamosin26-54 were synthesized by solid-phase synthesis with a purity of over 95%. Both Sparamosin and Sparamosin26-54 exhibit strong antimicrobial activity. More importantly, Sparamosin26-54 has strong antifungal activity and could inhibit the growth of a variety of yeasts and filamentous fungi. Based on the potent antimicrobial activities of Sparamosin and Sparamosin26-54, both peptides could be developed as alternatives for conventional antibiotics, antimicrobial agents, feed additives in aquaculture and livestock, preservatives, and mold inhibitors.

Abstract: Provided are a method and a kit for constructing a simplified genomic library. The method comprises: performing a non-specific amplification on a whole genome with a first pair of primers to obtain random amplified fragments; performing a specific amplification on the random amplified fragments with a second pair of primers to obtain the simplified genomic library.

Abstract: Provided are a method and device for analyzing a sequencing data result, and a sequencing library construction and sequencing method. The method for analyzing the sequencing data result includes: a sequencing data result of a sequencing library is acquired (S101), the sequencing library including a plurality of mixed samples, each of the samples corresponding to a label sequence combination, and different samples corresponding to different label sequence combinations, wherein each label sequence combination includes a plurality of label sequences, the sequencing data result comprises a sequencing fragment set obtained by sequencing the plurality of mixed samples, and the sequencing fragment set includes a plurality of disordered sequencing fragments; a label sequence combination of each of the sequencing fragments is determined (S102); and a sample corresponding to each of the sequencing fragments is determined according to the label sequence combination of each of the sequencing fragments (S103).

Abstract: A limited mode dispersion compensating optical fiber comprising four core areas, with the first area exhibiting a peak refractive index designated nc1, a second core area surrounding the first core area exhibiting a peak refractive index nc2, a third core area surrounding the second core area exhibiting a peak refractive index nc3, a fourth core area surrounding the third core area exhibiting a peak refractive index nc4 and a cladding area surrounding the fourth core area. The fourth core area is designed to have a low enough refractive index so as not to support additional modes. The limited mode dispersion compensating optical fiber supports the LP02 mode, and exhibits average dispersion more negative than −250 ps/nm/km.